Evidence map›Paper›PMID 42622902›Full record

ReviewMedical oncology (Northwood, London, England)2026

Synthetic and mechanistic outlines of magnetoelectric nanomedicine for targeted cancer therapy.

Neha Sharma, Ratneshwar Kumar Ratnesh, Anurag Chaudhary, Jay Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Neha SharmaDepartment of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut, UP, 250005, India.
Ratneshwar Kumar RatneshDepartment of Electronics and Communication Engineering, Netaji Subhas University of Technology, Delhi, 110078, India. ratneshwar.ratnesh@nsut.ac.in.
Anurag ChaudharyDepartment of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut, UP, 250005, India.
Jay SinghDepartment of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, UP, 221005, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synthesis of magnetoelectric nanoparticles (MENPs) has attracted increasing attention in the field of the treatment of cancer and other diseases worldwide. Recent developments in drug delivery systems like magnetic nanoparticle (MNP)-based platforms are particularly attractive as their motion and build-up at a target can be modulated by an external magnetic field, leading to highly selective delivery at diseased sites. The potential is built upon the magnetic properties of MENPs that enable imaging and targeting, transport of therapeutic agents, as well as bio functionality due to surface modifications. The majority of MENPs are formulated from superparamagnetic iron oxide nanoparticles (SPIONs) that are usually coated with materials such as polymers, liposomes, silica, or other biocompatible materials. Internationally, several MENP formulations containing common anticancer agents including paclitaxel, doxorubicin, docetaxel, cisplatin, and camptothecin have been formulated. These were advantages with respect to traditional magnetic drug carriers in terms of drug dose and release profiles. Besides drug delivery, MENPs are of great interest for theranostic applications which refer to the combination of therapy and diagnosis. The magnetoelectric (ME) nanoparticles are synthesized, functionalized, and used in biomedical arena are summarized and focused on their growing significance in cancer treatment and diagnostic imaging.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsMagnetite NanoparticlesNanomedicineNeoplasmsAnimalsHumansAntineoplastic AgentsMagnetite NanoparticlesCancer therapyDiagnosticHyperthermiaMagnetoelectric nanoparticlesSynthetic approaches

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.